The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01928082
Recruitment Status : Terminated (The fellow conducting the recruitment and screening left the institution)
First Posted : August 23, 2013
Results First Posted : March 7, 2018
Last Update Posted : March 7, 2018
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
The purpose of this study is to assess if estrogen replacement normalizes urinary calcium excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for differences in response to estrogen replacement in women with familial hypercalciuria compared to nonfamilial hypercalciuria.

Condition or disease Intervention/treatment Phase
Hypercalciuria Hypercalciuria, Familial Idiopathic Osteopenia Osteoporosis Drug: Transdermal estradiol Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
Actual Study Start Date : August 1, 2013
Actual Primary Completion Date : August 1, 2014
Actual Study Completion Date : August 1, 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bone Density
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Transdermal estradiol
Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
Drug: Transdermal estradiol
4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
Other Names:
  • Vivelle-Dot 0.05 mg/day
  • Vivelle-Dot 0.10 mg/day

Primary Outcome Measures :
  1. Absolute Change in 24 Hour Urinary Calcium Excretion [ Time Frame: 4 weeks, 8 weeks ]
    0 participants were measured because the study was terminated

Secondary Outcome Measures :
  1. Serum 1,25-dihydroxyvitamin D3 [ Time Frame: 4 weeks, 8 weeks ]
    0 participants were analyzed because the study was terminated

  2. Serum Bone Morphogenetic Protein 2 [ Time Frame: 4 weeks, 8 weeks ]
  3. Serum Sclerostin [ Time Frame: 4 weeks, 8 weeks ]

Other Outcome Measures:
  1. Serum Estradiol [ Time Frame: 4 weeks, 8 weeks ]
  2. Serum Total Calcium [ Time Frame: 4 weeks, 8 weeks ]
  3. Calculated Serum Ionized Calcium [ Time Frame: 4 weeks, 8 weeks ]
  4. Calculated Tubular Resorption of Calcium [ Time Frame: 4 weeks, 8 weeks ]
  5. Serum 25 Hydroxyvitamin D [ Time Frame: 4 weeks, 8 weeks ]
  6. Serum Parathyroid Hormone [ Time Frame: 4 weeks, 8 weeks ]
  7. Serum Phosphorus [ Time Frame: 4 weeks, 8 weeks ]
  8. Serum Osteocalcin [ Time Frame: 4 weeks, 8 weeks ]
  9. Serum Bone-specific Alkaline Phosphatase [ Time Frame: 4 weeks, 8 weeks ]
  10. Serum C-telopeptides of Type 1 Collagen [ Time Frame: 4 weeks, 8 weeks ]
  11. Serum Procollagen Type 1 N-terminal Propeptide [ Time Frame: 4 weeks, 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal women
  • Diagnosis of hypercalciuria
  • Diagnosis of low bone mass
  • Vitamin D replete (serum 25-hydroxyvitamin D level >35 ng/mL)

Exclusion Criteria:

  • Secondary causes of hypercalciuria (primary hyperparathyroidism, sarcoidosis, vitamin D excess, malignant neoplasm, and renal tubular acidosis)
  • Other metabolic bone disease (primary hyperparathyroidism, hyperthyroidism, hypercortisolemia, severe gastrointestinal disorders, liver cirrhosis, renal failure (Cr >1.5), active malignancy including multiple myeloma, rheumatological diseases, and Paget's disease of bone)
  • Use of medications affecting bone and calcium metabolism (corticosteroids in the previous 3 months, suppressive dose of thyroid hormone, calcium channel blockers, anti-convulsants, aromatase inhibitors, thiazolidinediones, and cyclosporine A)
  • History of coronary artery disease
  • Breast cancer or suspected estrogen-dependent neoplasia
  • Previous venous thromboembolic event
  • Stroke
  • Active liver disease
  • Tobacco use within the past 6 months
  • Negative colonoscopy within the previous 10 years or sigmoidoscopy within the previous 5 years
  • Negative mammogram within the previous 2 years
  • Negative Pap smear within the previous 3 years in women < or = 65 years old with an intact cervix
  • No vaginal bleeding within the prior 5 months.
  • Age > or = 70
  • > or = 20 years since last menstrual period or use of hormone replacement therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01928082

United States, Illinois
The University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Principal Investigator: Murray J Favus, MD University of Chicago


Responsible Party: University of Chicago Identifier: NCT01928082     History of Changes
Other Study ID Numbers: 12-0062
First Posted: August 23, 2013    Key Record Dates
Results First Posted: March 7, 2018
Last Update Posted: March 7, 2018
Last Verified: February 2018

Keywords provided by University of Chicago:
Hypercalciuria, Familial Idiopathic
Postmenopausal women

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Urological Manifestations
Signs and Symptoms
Polyestradiol phosphate
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female